Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis

Evidence of the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months has been emerging. To evaluate the immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months in a systematic review and meta-analysis. This meta-analysis included 12 studies with 6722 participants receiving QIV, 3575 participants receiving TIV, 4249 participants receiving full-dose QIV (F-QIV), and 3722 participants receiving half-dose QIV (H-QIV). Among children aged 6 to 35 months, QIV produces a better Immunogenicity against influenza B vaccine strains not contained in TIV. However, injection site reaction was more common for QIV, F-QIV showed superior efficacy for the B lineage, but fever and injection site pain was more frequently reported for F-QIV than H-QIV. These data support the immunogenicity and safety of quadrivalent inactivated influenza vaccine among children aged 6 to 35 months.针对6至35月龄儿童的四价灭活流感疫苗（quadrivalent inactivated influenza vaccine，QIV）免疫原性与安全性的相关证据正持续涌现。本研究通过系统评价与荟萃分析，旨在评估6至35月龄儿童接种四价灭活流感疫苗的免疫原性与安全性。本次荟萃分析共纳入12项研究，涉及6722名接种QIV的受试者、3575名接种三价灭活流感疫苗（trivalent inactivated influenza vaccine，TIV）的受试者、4249名接种全剂量四价灭活流感疫苗（full-dose QIV，F-QIV）的受试者，以及3722名接种半剂量四价灭活流感疫苗（half-dose QIV，H-QIV）的受试者。在6至35月龄儿童中，QIV针对TIV未覆盖的乙型流感毒株展现出更优的免疫原性。但QIV的注射部位不良反应更为常见；全剂量四价灭活流感疫苗针对乙型流感谱系展现出更优的防护效果，但相较于H-QIV，F-QIV更频繁地报告出现发热与注射部位疼痛症状。上述数据证实，6至35月龄儿童接种四价灭活流感疫苗具备可靠的免疫原性与安全性。